These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 34739863)

  • 21. Sustained Diet-Induced Remission in Pediatric Crohn's Disease Is Associated With Kynurenine and Serotonin Pathways.
    Ghiboub M; Boneh RS; Sovran B; Wine E; Lefèvre A; Emond P; Verburgt CM; Benninga MA; de Jonge WJ; Van Limbergen JE
    Inflamm Bowel Dis; 2023 May; 29(5):684-694. PubMed ID: 36637175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review.
    Hashash JG; Elkins J; Lewis JD; Binion DG
    Gastroenterology; 2024 Mar; 166(3):521-532. PubMed ID: 38276922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative Crohn's Disease Exclusion Diet and Exclusive Enteral Nutrition in Adults with Crohn's Disease: A Feasibility Randomised Controlled Trial.
    Wall CL; Bensley R; Glyn T; Haines M; Rowbotham D; Bissett I; Eglinton T; Gearry RB
    Nutrients; 2024 Jul; 16(13):. PubMed ID: 38999853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Crohn's Disease Exclusion Diet: A Comprehensive Review of Evidence, Implementation Strategies, Practical Guidance, and Future Directions.
    Sigall Boneh R; Westoby C; Oseran I; Sarbagili-Shabat C; Albenberg LG; Lionetti P; Manuel Navas-López V; Martín-de-Carpi J; Yanai H; Maharshak N; Van Limbergen J; Wine E
    Inflamm Bowel Dis; 2024 Oct; 30(10):1888-1902. PubMed ID: 37978895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
    van Linschoten RCA; Jansen FM; Pauwels RWM; Smits LJT; Atsma F; Kievit W; de Jong DJ; de Vries AC; Boekema PJ; West RL; Bodelier AGL; Gisbertz IAM; Wolfhagen FHJ; Römkens TEH; Lutgens MWMD; van Bodegraven AA; Oldenburg B; Pierik MJ; Russel MGVM; de Boer NK; Mallant-Hent RC; Ter Borg PCJ; van der Meulen-de Jong AE; Jansen JM; Jansen SV; Tan ACITL; van der Woude CJ; Hoentjen F;
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):343-355. PubMed ID: 36736339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is There Evidence of Crohn's Disease Exclusion Diet (CDED) in Remission of Active Disease in Children and Adults? A Systematic Review.
    Correia I; Oliveira PA; Antunes ML; Raimundo MDG; Moreira AC
    Nutrients; 2024 Mar; 16(7):. PubMed ID: 38613020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Use of the Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition for the Treatment of Crohn's Disease During Pregnancy.
    Ukovic B; Chapman B; Schulberg J; De Cruz P; Choy MC
    ACG Case Rep J; 2023 Jul; 10(7):e01078. PubMed ID: 37457641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolome Changes With Diet-Induced Remission in Pediatric Crohn's Disease.
    Ghiboub M; Penny S; Verburgt CM; Boneh RS; Wine E; Cohen A; Dunn KA; Pinto DM; Benninga MA; de Jonge WJ; Levine A; Van Limbergen JE
    Gastroenterology; 2022 Oct; 163(4):922-936.e15. PubMed ID: 35679949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical application of the Crohn's disease exclusion diet as therapy in an adult Australian population.
    Russell EE; Day AS; Dimitroff C; Trakman GL; Silva H; Bryant RV; Purcell L; Yao CK; Landorf E; Fitzpatrick JA
    J Gastroenterol Hepatol; 2024 Mar; 39(3):446-456. PubMed ID: 38059536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction.
    Logan M; Clark CM; Ijaz UZ; Gervais L; Duncan H; Garrick V; Curtis L; Buchanan E; Cardigan T; Armstrong L; Delahunty C; Flynn DM; Barclay AR; Tayler R; McDonald E; Milling S; Hansen RK; Gerasimidis K; Russell RK
    Aliment Pharmacol Ther; 2019 Sep; 50(6):664-674. PubMed ID: 31342536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reverse-engineered exclusive enteral nutrition in pediatric Crohn's disease: A pilot trial.
    Lee D; Braly K; Nuding M; Braly I; Hopp C; Twible H; Pope C; Hayden HS; Hoffman L; Zheng H; Wahbeh G; Suskind DL
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1135-1142. PubMed ID: 38558411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Swaminath A; Feathers A; Ananthakrishnan AN; Falzon L; Li Ferry S
    Aliment Pharmacol Ther; 2017 Oct; 46(7):645-656. PubMed ID: 28815649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
    Lewis JD; Sandler RS; Brotherton C; Brensinger C; Li H; Kappelman MD; Daniel SG; Bittinger K; Albenberg L; Valentine JF; Hanson JS; Suskind DL; Meyer A; Compher CW; Bewtra M; Saxena A; Dobes A; Cohen BL; Flynn AD; Fischer M; Saha S; Swaminath A; Yacyshyn B; Scherl E; Horst S; Curtis JR; Braly K; Nessel L; McCauley M; McKeever L; Herfarth H;
    Gastroenterology; 2021 Sep; 161(3):837-852.e9. PubMed ID: 34052278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enteral nutritional therapy for inducing remission of Crohn's disease.
    Zachos M; Tondeur M; Griffiths AM
    Cochrane Database Syst Rev; 2001; (3):CD000542. PubMed ID: 11686966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
    Peyrin-Biroulet L; Chapman JC; Colombel JF; Caprioli F; D'Haens G; Ferrante M; Schreiber S; Atreya R; Danese S; Lindsay JO; Bossuyt P; Siegmund B; Irving PM; Panaccione R; Cao Q; Neimark E; Wallace K; Anschutz T; Kligys K; Duan WR; Pivorunas V; Huang X; Berg S; Shu L; Dubinsky M;
    N Engl J Med; 2024 Jul; 391(3):213-223. PubMed ID: 39018531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.